LIQUID COMPOSITION STABILIZING BOTULINUM TOXIN Russian patent published in 2024 - IPC A61K9/08 A61K38/48 A61K47/18 A61K47/20 A61K47/26 

Abstract RU 2812790 C2

FIELD: medicine.

SUBSTANCE: group of inventions relates to a liquid composition for use in stabilizing botulinum toxin, containing (i) polysorbate 80 and serine or (ii) polysorbate 80, serine and methionine as active ingredients, where (i) the ratio of polysorbate 80 : serine is 1 mg/ml : 5 mM or more, or (ii) the polysorbate 80 : serine: methionine ratio is 1 mg/ml : 5–50 mm : 0.2 mM, and where the composition contains 0.001 mg/ml or more of polysorbate 80 by 40 U/ml botulinum toxin, also refers to a pharmaceutical composition made in liquid dosage form for blocking the presynaptic release of acetylcholine containing the liquid composition and botulinum toxin in as active ingredients, also refers to a method of stabilizing botulinum toxin, comprising the following: mixing a liquid composition containing (i) polysorbate 80 and serine or (ii) polysorbate 80, serine and methionine, with botulinum toxin, where (i) the ratio is polysorbate 80 : serine is 1 mg/ml : 5 mM or more, or (ii) the polysorbate 80 : serine: methionine ratio is 1 mg/ml : 5–50 mm : 0.2 mM, and where the composition contains 0.001 mg/ml or more of polysorbate 80 per 40 U/ml botulinum toxin, and also refers to the use of a liquid composition containing (i) polysorbate 80 and serine or (ii) polysorbate 80, serine and methionine, to stabilize botulinum toxin, where (i) the polysorbate 80 : serine ratio is 1 mg/ml: 5 mM or more, or (ii) the polysorbate 80 : serine: methionine ratio is 1 mg/ml : 5–50 mm : 0.2 mM, and where the composition contains 0.001 mg/ml or more of polysorbate 80 per 40 U/ml botulinum toxin.

EFFECT: group of inventions provides a liquid composition containing a stabilizer that is not derived from an animal source, and thus, a patient who is administered a pharmaceutical composition containing botulinum toxin can be guaranteed safety from the potential risk of infection by a blood-derived pathogen or infectious microorganism, and ensuring stability during storage and distribution, since the activity of botulinum toxin is maintained at room temperature for a long time.

8 cl, 4 tbl, 3 dwg

Similar patents RU2812790C2

Title Year Author Number
LIQUID PHARMACEUTICAL COMPOSITION OF BOTULINUM TOXIN 2008
  • Dzjung Khun Kho
  • Jang Gi Khueok
  • Kim Khak Voo
  • Voo Khee Dong
  • Rkhee Chang Khoon
RU2440825C2
STABLE LIQUID COMPOSITION CONTAINING BOTULINUM TOXIN 2017
  • Yim, Hyeona
  • Kim, Cheong-Sei
RU2728776C1
LYOPHILISED PREPARATION OF BOTULINUM TOXIN 2012
  • Dzung Khiung Kho
  • Jang Gi Khieok
  • Rkhee Chang Khoon
  • Kim Khak Voo
  • Kim Sung Bum
  • Baek Seung Khvan
RU2574011C2
LYOPHILISED PREPARATION OF BOTULINUM TOXIN 2012
  • Dzung, Khiung Kho
  • Yang, Gi Khieok
  • Rkhee, Chang Khoon
  • Kim, Khak Voo
  • Kim, Sung Bum
  • Baek, Seung Khvan
RU2640922C1
LIQUID COMPOSITION OF NEUROTOXIN STABILIZED WITH TRYPTOPHAN OR TYROSINE 2017
  • Yarstad, Anders
  • Friis, Anna
  • Shtal, Ulf
  • Gurell, Ann
  • Agren, Barbro
  • Edstrom, Emiliya
  • Pikett, Endryu
RU2741497C2
COMPOSITION FOR PROTEIN PHARMACEUTICAL MEDICATION WITHOUT ADDITION OF HUMAN SERUM ALBUMEN (HSA) 2004
  • Frevert Jurgen
RU2354366C2
COMPOSITION FOR PROTEIN PHARMACEUTICAL PREPARATION WITH NO ADDED HUMAN SERUM ALBUMIN (HSA) 2004
  • Frevert Jurgen
RU2491927C2
Liquid composition containing botulinum toxin and a stabilizing agent, and a method for its preparation 2017
  • Lee, Chee Gun
  • Oum, Ji Khyun
RU2748653C2
STABILIZED NON-PROTEIN COMPOSITIONS OF CLOSTRIDIAL TOXIN 2017
  • Abiad Maurice
  • Dani Bhas
  • Shalaev Evgenyi
RU2762607C2
PHARMACEUTICAL COMPOSITION, INCLUDING A PH20 VARIANT OF HUMAN HYALURONIDASE, AND A MEDICINAL PRODUCT FOR SUBCUTANEOUS ADMINISTRATION 2020
  • Park, Soon Jae
  • Chung, Hye-Shin
  • Lee, Seung Joo
  • Kim, Kyuwan
  • Byun, Minsoo
  • Nam, Ki Seok
RU2810952C2

RU 2 812 790 C2

Authors

Kim, Wanseop Paul

Kim, Yeong-Mok

Park, Gi-Sik

Park, Jae-Min

Lee, Ae-Yeon

Dates

2024-02-02Published

2019-11-29Filed